AMH Equity Ltd Has $608,000 Stock Position in OptimizeRx Co. (NASDAQ:OPRX)

AMH Equity Ltd increased its holdings in OptimizeRx Co. (NASDAQ:OPRX) by 25.0% during the fourth quarter, HoldingsChannel reports. The fund owned 125,000 shares of the company’s stock after acquiring an additional 25,000 shares during the quarter. AMH Equity Ltd’s holdings in OptimizeRx were worth $608,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its holdings in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares in the last quarter. Quest Partners LLC grew its holdings in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares in the last quarter. SG Americas Securities LLC bought a new stake in OptimizeRx during the fourth quarter worth $51,000. Barclays PLC raised its position in OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after buying an additional 21,060 shares during the last quarter. Finally, Greenwood Capital Associates LLC lifted its stake in OptimizeRx by 8.0% during the 3rd quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after acquiring an additional 4,999 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on OPRX. JMP Securities reiterated a “market outperform” rating and issued a $8.00 target price on shares of OptimizeRx in a research note on Thursday, February 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Lake Street Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of OptimizeRx in a research note on Tuesday, December 24th. B. Riley cut their target price on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Stock Down 3.8 %

OptimizeRx stock opened at $5.11 on Thursday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $94.13 million, a P/E ratio of -3.84 and a beta of 1.38. The firm has a 50 day moving average price of $5.44 and a 200-day moving average price of $6.17. OptimizeRx Co. has a twelve month low of $3.78 and a twelve month high of $16.65.

Insider Buying and Selling at OptimizeRx

In other OptimizeRx news, CEO William J. Febbo acquired 20,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 601,253 shares in the company, valued at $3,012,277.53. This trade represents a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.10% of the stock is owned by corporate insiders.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.